News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,667 Results
Type
Article (14239)
Company Profile (281)
Press Release (253147)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79524)
Career Advice (153)
Deals (13227)
Drug Delivery (35)
Drug Development (50459)
Employer Resources (31)
FDA (5721)
Job Trends (5132)
News (144424)
Policy (10031)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (51)
Alliances (21667)
ALS (63)
Alzheimer's disease (845)
Antibody-drug conjugate (ADC) (98)
Approvals (5746)
Artificial intelligence (122)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (51)
Brain cancer (20)
Breast cancer (150)
Cancer (1426)
Cardiovascular disease (116)
Career advice (133)
Career pathing (2)
CAR-T (112)
Cell therapy (317)
Cervical cancer (8)
Clinical research (41038)
Collaboration (533)
Compensation (256)
Complete response letters (13)
COVID-19 (1034)
CRISPR (39)
C-suite (158)
Cystic fibrosis (76)
Data (1454)
Denatured (11)
Depression (29)
Diabetes (134)
Diagnostics (1297)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (89)
Earnings (29776)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48434)
Executive appointments (449)
FDA (6400)
Featured Employer (30)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (496)
Gene editing (93)
Generative AI (10)
Gene therapy (242)
GLP-1 (364)
Government (1078)
Grass and pollen (2)
Guidances (20)
Healthcare (6593)
Huntington's disease (22)
IgA nephropathy (22)
Immunology and inflammation (90)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (112)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (64)
Interviews (17)
IPO (7269)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (206)
Leadership (3)
Legal (1386)
Liver cancer (32)
Lung cancer (201)
Lymphoma (96)
Machine learning (3)
Management (7)
Manufacturing (136)
MASH (52)
Medical device (2597)
Medtech (2598)
Mergers & acquisitions (6281)
Metabolic disorders (383)
Multiple sclerosis (52)
NASH (13)
Neurodegenerative disease (64)
Neuropsychiatric disorders (25)
Neuroscience (1241)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1663)
Now hiring (22)
Obesity (192)
Opinion (102)
Ovarian cancer (61)
Pain (41)
Pancreatic cancer (54)
Parkinson's disease (119)
Partnered (8)
Patents (125)
Patient recruitment (73)
Peanut (35)
People (25615)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14493)
Phase II (19091)
Phase III (12069)
Pipeline (786)
Policy (44)
Postmarket research (852)
Preclinical (6095)
Press Release (30)
Prostate cancer (59)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (287)
Real estate (1418)
Recruiting (12)
Regulatory (8615)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (58)
Series A (98)
Series B (62)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1455)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1974)
State (1)
Stomach cancer (4)
Supply chain (22)
Tariffs (6)
The Weekly (36)
United States (12936)
Vaccines (211)
Venture capitalists (32)
Weight loss (109)
Women's health (15)
Worklife (2)
Date
Last 7 days (366)
Last 30 days (1362)
Last 365 days (19448)
2025 (5845)
2024 (20551)
2023 (22414)
2022 (26823)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (41)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17287)
Australia (2931)
California (3768)
Canada (1121)
China (345)
Colorado (145)
Connecticut (149)
Delaware (97)
Europe (37184)
Florida (455)
Georgia (115)
Idaho (16)
Illinois (226)
India (10)
Indiana (91)
Iowa (2)
Japan (73)
Kansas (61)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (466)
Massachusetts (2984)
Michigan (70)
Minnesota (144)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (943)
New Mexico (12)
New York (1015)
North Carolina (543)
North Dakota (4)
Northern California (1663)
Ohio (111)
Oklahoma (9)
Oregon (21)
Pennsylvania (717)
Puerto Rico (5)
Rhode Island (18)
South America (208)
South Carolina (4)
Southern California (1455)
Tennessee (25)
Texas (436)
Utah (52)
Virginia (76)
Washington D.C. (30)
Washington State (345)
Wisconsin (14)
267,667 Results for "siteone therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SiteOne Therapeutics Announces Positive Phase 1 Clinical Data for STC-004, a Novel NaV1.8 Inhibitor in Development for the Non-Opioid Treatment of Pain
February 4, 2025
·
2 min read
Press Releases
SiteOne Therapeutics Announces a $100 Million Series C Financing to Advance Selective Ion Channel Modulators as Non-opioid Treatments for Pain
December 18, 2024
·
4 min read
Biotech Bay
SiteOne Therapeutics Awarded up to $15M Grant to Develop NaV1.8 Inhibitor as Non-Opioid Therapeutic for Pain
SiteOne Therapeutics, Inc. today announced that it has received a grant (UG3DA058552) for up to $15 million from the National Institute on Drug Abuse (NIDA) for the development of STC-004, an investigational, non-opioid treatment for acute and chronic pain conditions.
May 18, 2023
·
4 min read
Business
SiteOne Therapeutics Announces Collaboration and License Agreement with Vertex Pharmaceuticals to Advance NaV1.7 Inhibitors for the Treatment of Pain
SiteOne will be responsible for research and early preclinical development activities; Vertex will be responsible for development, and commercialization.
January 19, 2022
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Business
SiteOne Therapeutics Names Scientific Founder John Mulcahy, Ph.D., as Chief Executive Officer
SiteOne Therapeutics Inc., a private biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced the appointment of John Mulcahy, Ph.D., as chief executive officer
March 23, 2021
·
3 min read
Press Releases
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
April 17, 2025
·
13 min read
Press Releases
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
April 15, 2025
·
7 min read
Press Releases
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
April 21, 2025
·
3 min read
1 of 26,767
Next
